A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society-Reference-Cited by-同舟云学术

A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society

Published:2020 Issue:7-8 Volume:43 Page:333-339
ISSN:2296-5270
Container-title:Oncology Research and Treatment
language:en
Short-container-title:Oncol Res Treat

Author:

Bergmann Lothar,Grünwald Viktor,Maute Luise,Grimm Marc-Oliver,Weikert Steffen,Schleicher Jan,Klotz Theodor,Greiner Jochen,Flörcken Anne,Hartmann Arndt,Gauler Thomas

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology

Reference22 articles.

1. Ahrens M, Scheich S, Hartmann A, Bergmann L; IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer Society. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options. Oncol Res Treat. 2019;42(3):128–35.

2. Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. Eur Urol. 2019 Aug;76(2):151–6.

3. Miller K, Bergmann L, Doehn C, Gschwend JE, Kuczyk MA. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urol. 2019, Epub ahead of print. German.

4. Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, et al. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. Eur Urol. 2017 Mar;71(3):426–36.

5. Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol. 2015 Apr;67(4):740–9.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse renal outcomes following targeted therapies in renal cell carcinoma: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-06-26

2. C-type lectin 2D (CLEC2D) is upregulated in clear cell renal cell carcinoma (ccRCC) tissues and predicts poor prognosis;Heliyon;2024-03

3. Advances in the regulatory mechanisms of mTOR in necroptosis;Frontiers in Immunology;2023-12-18

4. PECAM-1 mediates temsirolimus-induced increase in neutrophil transendothelial migration that leads to lung injury;Biochemical and Biophysical Research Communications;2023-11

5. The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non‐clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database;Cancer Medicine;2023-10-31